Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement therapeutics; history and current progress.

B Paul Morgan1, Claire L Harris

  • 1Department of Medical Biochemistry and Immunology, UWCM, Heath Park, Cardiff CF14 4XN, Wales, UK. morganbp@cardiff.ac.uk

Molecular Immunology
|August 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immunology·2026
Same author

Absence of complement terminal pathway activity in C6-deficient mice prolongs survival in a mouse model of severe malarial infection.

Immunobiology·2025
Same author

CD59, Disulphide-Locked Human C9 and Horse C9 Inhibit Human Membrane Attack Complex Assembly by Similar Mechanisms.

Immunology·2025
Same author

Complement dysregulation in human tauopathies.

Brain pathology (Zurich, Switzerland)·2025
Same author

Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men.

American journal of physiology. Endocrinology and metabolism·2025
Same journal

m6A modification of LINC00458 enhances HMOX1 stability via ELAVL1 recruitment to promote ferroptosis and aggravate asthma.

Molecular immunology·2026
Same journal

Overexpression of Hes1 inhibits cigarette smoke-induced mitochondrial apoptosis in AT2 cells by activating the Pgc-1α/Tfam signaling pathway.

Molecular immunology·2026
Same journal

Progesterone promotes favorable pregnancy outcomes in recurrent spontaneous, abortion by attenuating NK Cell overactivation and upregulating the cAMP/PKA/CREB signaling axis.

Molecular immunology·2026
Same journal

Oleanolic acid alleviates hepatic fibrosis by inhibiting liver macrophage recruitment and polarization.

Molecular immunology·2026
Same journal

Cordycepin attenuates diabetic nephropathy by dual-pathway activation of TFEB to restore autophagy and ameliorate podocyte injury.

Molecular immunology·2026
Same journal

Endothelial-derived TWEAK drives granulosa cell apoptosis in PCOS via the Fn14-oxidative stress axis.

Molecular immunology·2026
See all related articles

The complement system is crucial for immunity but can cause disease. This review covers anti-complement therapies, from small molecules to engineered biologics, for treating complement-mediated pathologies.

Area of Science:

  • Immunology
  • Pharmacology
  • Biochemistry

Background:

  • The complement system is essential for immune surveillance and host defense.
  • Dysregulation of the complement cascade contributes to various inflammatory diseases and injury.
  • Therapeutic interventions can also trigger complement-mediated pathologies.

Purpose of the Study:

  • To review the historical development of anti-complement therapeutics.
  • To describe the diverse range of reagents developed to treat complement-mediated conditions.
  • To discuss recent advancements and future directions in anti-complement therapy.

Main Methods:

  • Literature review of historical and current anti-complement therapeutic strategies.
  • Analysis of small molecule inhibitors, peptides, and biological agents.

Related Experiment Videos

  • Evaluation of complement regulatory proteins and antibody-based inhibitors.

    • Main Results:

    • A wide array of anti-complement agents have been developed, including natural products, synthetic peptides, and engineered biologics.
    • Recombinant antibody fragments and complement regulatory protein mimics show therapeutic promise.
    • Targeted drug delivery to inflammatory sites enhances anti-complement therapy efficacy.

    Conclusions:

    • Anti-complement therapies offer a promising approach for managing inflammatory diseases and injuries.
    • Ongoing research focuses on refining existing agents and developing novel strategies for targeted delivery.
    • The field is rapidly evolving, with potential applications in both acute and chronic inflammatory conditions.